AXIM Biotechnologies, Inc. and Medical Marijuana, Inc. have entered into a strategic alliance focused on researching and developing applications for AXIM's patented water-soluble cannabinoid technology. The collaboration centers on AXIM's U.S. Patent No. 11,542,226 B2, which addresses a fundamental limitation of traditional cannabinoids: their inability to dissolve in water, significantly impairing absorption by the body.
Under the agreement, AXIM assigned Medical Marijuana, Inc. a fifty percent right, title, and economic interest in the patent and all associated intellectual property. This assignment includes rights to existing and future U.S. and foreign patents and applications, licensing, enforcement, and monetization proceeds, and claims for past infringement and accrued royalties. Medical Marijuana, Inc. paid $600,000 to AXIM as consideration for this assignment through the issuance of a secured promissory note.
Concurrently, the companies entered into a Consulting Agreement where AXIM will provide research and development services focused on developing applications for the patent technology. The agreement has an initial non-cancellable term of one year expiring in January 2027, with Medical Marijuana, Inc. paying AXIM $62,500 per month for these services.
The patented technology represents a significant advancement in cannabinoid delivery systems. Through patented molecular engineering, the technology links cannabinoids to complementary compounds, substantially improving their delivery mechanisms and therapeutic effectiveness. The engineered polyfunctional cannabinoids are more than 300 times more water-soluble than natural cannabinoids, enabling significantly improved absorption and therapeutic delivery.
Catalina Valencia, AXIM President, stated that the water solubility of CBD and other cannabinoids represents a significant development for improved administration and increased potency. "We believe that the Patent could result in the development of a drug or treatment, most likely in the form of sublingual administration, able to treat a variety of conditions including anxiety or seizures," Valencia said. More information about AXIM's broader diagnostic technology platform can be found at https://www.aximbiotech.com.
Dr. Scott, Medical Marijuana, Inc. Chairman and President, expressed confidence in AXIM's research and development capabilities. "The potential for developing enhanced administration of water soluble CBD and other cannabinoids for certain ailments and conditions is a major development for MJNA," Dr. Scott stated. "In addition, MJNA already has significant knowledge and exposure to the cannabinoid market and enjoys relationships in that arena."
The technological advantages extend beyond improved solubility. These polyfunctional constructs are engineered to produce more potent responses and efficacy than individual cannabinoid molecules, potentially allowing for lower therapeutic doses while avoiding toxic side effects associated with higher concentrations. The technology offers treatment potential for conditions where traditional lipophilic (oil-based) cannabinoids have demonstrated limited bioavailability, including development of sublingual applications for anxiety and other indications.
This alliance represents a convergence of complementary expertise in the cannabinoid space. AXIM brings its patented water-soluble technology and research capabilities, while Medical Marijuana, Inc. contributes market knowledge and established industry relationships. The collaboration could accelerate the development of cannabinoid-based treatments with improved efficacy and reduced side effects, potentially expanding treatment options for conditions that have shown limited response to traditional cannabinoid formulations.
The strategic alliance comes at a time when cannabinoid research continues to expand into new therapeutic areas. The ability to create water-soluble formulations addresses one of the most significant barriers to effective cannabinoid delivery, potentially opening new avenues for pharmaceutical development and consumer product innovation. As research progresses, the technology could lead to more predictable dosing, faster onset of action, and improved patient outcomes across multiple medical conditions.
